Denise Wolleschak, Thomas S. Mack, Florian Perner, Stephanie Frey, Tina M. Schnöder, Marie-Christine Wagner, Christine Höding, Marina C. Pils, Andreas Parkner, Stefanie Kliche, Burkhart Schraven, Katrin Hebel, Monika Brunner-Weinzierl, Satish Ranjan, Berend Isermann, Daniel B. Lipka, Thomas Fischer, Florian H. Heidel. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. haematol [Internet]. 2014May31 [cited 2024Nov.22];99(6):e90-e93. Available from: https://haematologica.org/article/view/7069